Olanzapine induced Diabetic ketoacidosis and neuroleptic malignant syndrome
By: D.S.A. Wickramasinghe, D.N. Weeratunga, S.U. Rupasinghe, M.U.D. Gunarathna and J.D.V.C. Lekamwasam
Open Access
|Nov 2015Abstract
Introduction: Neuroleptic malignant syndrome (NMS) is an uncommon life threatening adverse reaction with the use of atypical antipsychotics like olanzapine. In addition, Olanzapine therapy is associated with increased incidence of diabetes. Here we describe a rare occurrence of Diabetes Keto Acidosis (DKA) and NMS in a young male treated with Olanzapine.
DOI: https://doi.org/10.4038/jrcs.v20i1.8 | Journal eISSN: 1391-1244
Language: English
Page range: 26 - 26
Published on: Nov 1, 2015
Published by: Ruhunu Clinical Society
In partnership with: Paradigm Publishing Services
© 2015 D.S.A. Wickramasinghe, D.N. Weeratunga, S.U. Rupasinghe, M.U.D. Gunarathna, J.D.V.C. Lekamwasam, published by Ruhunu Clinical Society
This work is licensed under the Creative Commons License.